Quantisnow Logo
Dashboard

SEC Form 15-12G filed by DICE Therapeutics Inc.

$DICE
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DICE alert in real time by email
15-12G 1 d496392d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-40794

 

 

DICE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

400 East Jamie Court, Suite 300

South San Francisco, California 94080

Telephone: (650) 566-1420

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common stock, $0.0001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☒

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☐

Rule 15d-22(b)

   ☐

Approximate number of holders of record as of the certification or notice date: One holder

Pursuant to the requirements of the Securities Exchange Act of 1934, DICE Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: August 21, 2023     DICE Therapeutics, Inc.
    By:  

/s/ Philip L. Johnson

    Name:   Philip L. Johnson
    Title:   President

 

 

 

 
Get the next $DICE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DICE

DatePrice TargetRatingAnalyst
5/24/2023$38.00Equal Weight
Wells Fargo
5/22/2023$71.00Buy
Canaccord Genuity
3/31/2023$56.00Buy
Needham
3/1/2023Outperform
TD Cowen
3/1/2023Outperform
Cowen
11/15/2022$65.00Buy
Guggenheim
9/14/2022$36.00Overweight
Cantor Fitzgerald
9/7/2022$37.00Buy
Stifel
More analyst ratings

$DICE
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Lilly Completes Acquisition of DICE Therapeutics

    INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Lilly Announces Extension of Tender Offer to Acquire DICE

    INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q

    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

    NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

    $BG
    $DICE
    $KDNY
    $QUOT
    Packaged Foods
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DICE
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DICE
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DICE
 SEC Filings

See more

$DICE
 Leadership Updates

Live Leadership Updates

See more

  • ShouTi Appoints Sharon Tetlow to Board of Directors

    ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

    $CBIO
    $DICE
    $VALN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

  • DICE Therapeutics Expands Management Team and Board of Directors

    Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e

    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DICE
 Financials

Live finance-specific insights

See more

  • Lilly Completes Acquisition of DICE Therapeutics

    INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

    Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal

    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DICE
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more